Table of Contents Author Guidelines Submit a Manuscript
Bone Marrow Research
Volume 2016 (2016), Article ID 3645623, 6 pages
http://dx.doi.org/10.1155/2016/3645623
Research Article

Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare

1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Box 298 Avenue, New York, NY 10065, USA
2Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington St., Box 63, Boston, MA 02111, USA
3Division of Hematology/Oncology, Department of Medicine, Tufts Medical Center, 800 Washington St., Box 245, Boston, MA 02111, USA
4Center for Health Solutions, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington St., Box 345, Boston, MA 02111, USA

Received 29 July 2016; Accepted 28 September 2016

Academic Editor: Paolo De Fabritiis

Copyright © 2016 Gunjan L. Shah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. C. Pasquini and Z. Wang, “Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2013,” http://www.cibmtr.org
  2. J. F. Piccirillo, A. Vlahiotis, L. B. Barrett, K. L. Flood, E. L. Spitznagel, and E. W. Steyerberg, “The changing prevalence of comorbidity across the age spectrum,” Critical Reviews in Oncology/Hematology, vol. 67, no. 2, pp. 124–132, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Labonté, T. Iqbal, M. A. Zaidi et al., “Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma,” Biology of Blood and Marrow Transplantation, vol. 14, no. 9, pp. 1039–1044, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Saad, A. Mahindra, M.-J. Zhang et al., “Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma,” Biology of Blood and Marrow Transplantation, vol. 20, no. 3, pp. 402–408.e1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Kleber, G. Ihorst, M. Terhorst et al., “Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score,” Blood Cancer Journal, vol. 1, no. 9, article e35, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Buijt, G. J. Ossenkoppele, C. A. Uyl-De Groot, and P. C. Huijgens, “Costs of intensive treatment and follow-up of patients with multiple myeloma,” Anti-Cancer Drugs, vol. 9, no. 10, pp. 889–897, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Pandya, S. Hashmi, N. Khera et al., “Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma,” Clinical transplantation, vol. 28, no. 10, pp. 1084–1091, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Jagannath, D. H. Vesole, M. Zhang et al., “Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma,” Bone Marrow Transplantation, vol. 20, no. 6, pp. 445–450, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. C. T. Kouroukis, B. J. O'Brien, A. Benger et al., “Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma,” Leukemia and Lymphoma, vol. 44, no. 1, pp. 29–37, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Moeremans and L. Annemans, “An update: health economics of managing multiple myeloma,” European Journal of Cancer, vol. 42, no. 11, pp. 1684–1691, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. “About the SEER Program,” Surveillance Research Program, NCI, http://seer.cancer.gov/about/overview.html
  12. A.-M. Noone, J. L. Lund, A. Mariotto et al., “Comparison of SEER treatment data with medicare claims,” Medical Care, vol. 54, no. 9, pp. e55–e64, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Potosky, G. Riley, and J. Lubitz, “Potential for cancer related health services research using a linked Medicare-tumor registry database,” Medical Care, vol. 31, pp. 732–748, 1993. View at Google Scholar
  14. “CMS Manual System Pub. 100-20 One-Time Notification,” 2003
  15. C. N. Klabunde, A. L. Potosky, J. M. Legler, and J. L. Warren, “Development of a comorbidity index using physician claims data,” Journal of Clinical Epidemiology, vol. 53, no. 12, pp. 1258–1267, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. J. H. Garvin, A. Redd, D. Bolton et al., “Exploration of ICD-9-CM coding of chronic disease within the Elixhauser Comorbidity Measure in patients with chronic heart failure,” Perspectives in Health Information Management, vol. 10, p. 1, 2013. View at Google Scholar · View at Scopus
  17. J. Newhouse, “Medical Care Price Indices: Problems and Opportunities,” 2001
  18. “U.S. Bureau of Labor Statistics,” http://www.bls.gov/home.htm
  19. J.-L. Harousseau, M. Attal, H. Avet-Loiseau et al., “Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial,” Journal of Clinical Oncology, vol. 28, no. 30, pp. 4621–4629, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. P. G. Richardson, E. Weller, S. Lonial et al., “Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma,” Blood, vol. 116, no. 5, pp. 679–686, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. S. K. Kumar, S. V. Rajkumar, A. Dispenzieri et al., “Improved survival in multiple myeloma and the impact of novel therapies,” Blood, vol. 111, no. 5, pp. 2516–2520, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Ozaki, T. Harada, T. Saitoh et al., “Survival of multiple myeloma patients aged 65–70 years in the era of novel agents and autologous stem cell transplantation,” Acta Haematologica, vol. 132, no. 2, pp. 211–219, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Woldemichael, E. Onukwugha, Z. Zheng, N. Hanna, B. S. Seal, and C. D. Mullins, “The impact of comorbidity on costs and effects of second-line treatment among elderly metastatic colon cancer patients,” Journal of Clinical Oncology, vol. 32, supplement 3, abstract 536, 2014. View at Google Scholar
  24. D. J. Genther and C. G. Gourin, “Effect of comorbidity on short-term outcomes and cost of care after head and neck cancer surgery in the elderly,” Head and Neck, vol. 37, no. 5, pp. 685–693, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. S. H. Taplin, W. Barlow, N. Urban et al., “Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care,” Journal of the National Cancer Institute, vol. 87, no. 6, pp. 417–426, 1995. View at Publisher · View at Google Scholar · View at Scopus
  26. C. S. Hollenbeak, B. C. Stack Jr., S. M. Daley, and J. F. Piccirillo, “Using comorbidity indexes to predict costs for head and neck cancer,” Archives of Otolaryngology—Head and Neck Surgery, vol. 133, no. 1, pp. 24–27, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. A. M. Bell, M. Corral, J. R. Penrod et al., “New drugs not major cost drivers for lung cancer care,” American Journal of Pharmacy Benefits, vol. 6, no. 3, pp. e50–e59, 2014. View at Google Scholar · View at Scopus
  28. M. A. Gertz, S. M. Ansell, D. Dingli et al., “Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative,” Mayo Clinic Proceedings, vol. 83, no. 10, pp. 1131–1135, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. D. E. Reece, C. Bredeson, W. S. Pérez et al., “Autologous stem cell transplantation in multiple myeloma patients <60 vs 60 years of age,” Bone Marrow Transplant, vol. 32, no. 12, pp. 1135–1143, 2003. View at Google Scholar
  30. N. S. Majhail, L. W. Mau, E. M. Denzen, and T. J. Arneson, “Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large National Private Claims Database,” Bone Marrow Transplantation, vol. 48, no. 2, pp. 294–300, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Sharma, M.-J. Zhang, X. Zhong et al., “Older patients with myeloma derive similar benefit from autologous transplantation,” Biology of Blood and Marrow Transplantation, vol. 20, no. 11, pp. 1796–1803, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Sonneveld, H. Goldschmidt, L. Rosiñol et al., “Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials,” Journal of Clinical Oncology, vol. 31, no. 26, pp. 3279–3287, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. P. L. McCarthy, T. Hahn, A. Hassebroek et al., “Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995–2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age,” Biology of Blood and Marrow Transplantation, vol. 19, no. 7, pp. 1116–1123, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. V. Mishra, S. Andresen, L. Brinch et al., “Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study,” Bone Marrow Transplantation, vol. 35, no. 12, pp. 1149–1153, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Van Agthoven, C. M. Segeren, I. Buijt et al., “A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma: A Prospective Randomised Phase III Study,” European Journal of Cancer, vol. 40, no. 8, pp. 1159–1169, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. J. A. Jones, M. H. Qazilbash, Y.-C. T. Shih, S. B. Cantor, C. D. Cooksley, and L. S. Elting, “In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: clinical and economic outcomes from the Nationwide Inpatient Sample,” Cancer, vol. 112, no. 5, pp. 1096–1105, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. “Measures that are limited or not available in the data,” NCI, http://appliedresearch.cancer.gov/seermedicare/considerations/measures.html
  38. J. J. Young, S. Roffers, L. Ries, and A. Fritz, EER Summary Staging Manual—2000: Codes and Coding Instructions, Edited by Hurlbut, National Cancer Institute, Bethesda, Md, USA, 2001.
  39. J. Ruhl, M. Adamo, L. Dickie, L. Sun, and C. Johnson, Hematopoietic and Lymphoid Neoplasm Coding Manual, National Cancer Institute, Bethesda, Md, USA, 2014.
  40. Require SEER Site Specific Factors for Collaborative Stage, National Cancer Institute, Bethesda, Md, USA, 2014, http://seer.cancer.gov/tools/ssf/.
  41. J. L. Warren, C. N. Klabunde, D. Schrag, P. B. Bach, and G. F. Riley, “Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population,” Medical Care, vol. 40, no. 8, supplement, pp. IV-3–IV-18, 2002. View at Google Scholar · View at Scopus